BRAF and non-small cell lung carcinoma: Finally, in a retrospective analysis of 30 patients with BRAF nonV600E mutated NSCLC, G469A and L597R mutations (that are associated with high kinase activity) were associated with response to BRAF + MEK inhibitors.